0
Article |

Pentylenetetrazol (Metrazol) in Mental Deficiency

H. H. BERMAN, M.D.; M. LAZAR, M.D.; O. NOE, M.D.; H. SCHILLER, M.D.
AMA Am J Dis Child. 1957;94(3):231-233. doi:10.1001/archpedi.1957.04030040013003.
Text Size: A A A
Published online

Introduction  Pentylenetetrazol (Metrazol) has been used as a respiratory stimulant for 30 years and as a convulsant for 20 years. The pharmacology and chemistry of the drug was described in 1937 by Giessen,1 who gave a bibliography of the German literature up to that time. The use of pentylenetetrazol as a convulsant is well documented in the American literature. During the past five years, articles224 have appeared on its use in senile and arteriosclerotic patients, with somewhat contradictory results; the majority felt that it in some way stimulated the patients, reducing the confusion, and caused a general feeling of well being. The beneficial effects have been attributed to the increased metabolism in the brain. Giessen pointed out that pentylenetetrazol increases the cerebral circulation and the amount of oxygen taken up. On the basis of this supposition, it was decided to try pentylenetetrazol on different groups of retarded children

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Correspondence

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs